City of Hope has one of the most influential diabetes research programs in the world. Our scientists’ work has revolutionized the understanding and treatment of the disease and continues today with exciting developments in cell transplantation, gene regulation, immune tolerance, and gaining systemic understanding of diabetes as a complex, multifaceted disease.
Within Diabetes Research is the Department of Diabetes and Metabolic Diseases Research. Scientists in that department work in two divisions:
Molecular Diabetes Research
Developmental and Translational Diabetes and Endocrine Research
City of Hope’s leadership in diabetes began decades ago when the “father of endocrinology,” Rachmiel Levine, M.D., launched diabetes research at City of Hope. Levine had, in the 1940s, identified the principal cause of the illness: a reduction in our body’s ability to stimulate glucose entry in the cells, directly linked to the insulin production.
City of Hope researchers, such as Rama Natarajan, Ph.D., are making landmark contributions to the fight against diabetes.
Today, City of Hope researchers continue to make landmark contributions to the fight against diabetes. Recognized nationwide for our innovative biomedical research, we are home to some of the most creative minds in science. Our strength lies in collaboration – leveraging the talents of investigators across departments and across the institution and rapidly translating scientific discoveries into new treatments. By working together and sharing results, researchers and clinicians are able to put theories into practice. As a result, excellence in one area fuels advancements in all areas.
City of Hope’s mission in diabetes research is to improve the quality of life for patients, prevent complications from the disease, and ultimately, establish a cure. At City of Hope, we’ve achieved many milestones in the field and are now pursuing the next generation of diabetes treatments in our efforts to end the devastation of the disease and usher in a new era of healing and hope.
Diabetes basic research is housed in the Leslie & Susan Gonda (Goldschmied) Diabetes & Genetic Research Center, which was recently expanded to provide urgently needed laboratory space. City of Hope researchers are using this lab space in their race to find ways to understand, control and cure diabetes, which continues to grow as a major public health threat.
An epidemic reaching pandemic proportions
Diabetes is rapidly progressing from epidemic to pandemic. The Centers for Disease Control and Prevention predicts that by the year 2050, if current epidemiological trends continue, one in every three people in the U.S. could suffer from diabetes at some point in their life. Diabetes is a global issue as well, as one of the world’s leading causes of death, disability and lost economic growth. Worldwide, health expenditures to treat and prevent the disease and its complications continue to grow, with $465 billion spent in 2011 alone.
Scientists in basic research provide the foundation for new therapies and approaches to battling diabetes. Our work touches on all aspects of the disease, including heart and kidney complications. Read more about our current projects and the work of each division by clicking on the tabs above.
Our clinical program and translational research
At City of Hope, our experience in the area of diabetes, including established analytic, molecular and clinical resources, have enabled us to rapidly translate emerging scientific concepts into new treatments. Our mission is to ensure that breakthroughs from the basic research of scientists in the Department of Diabetes and Metabolic Diseases Research are then rapidly translated into clinical settings where they can impact patients. The
Department of Clinical Diabetes, Endocrinology & Metabolism
is currently conducting a number of important clinical research programs to help put our basic and clinical biomedical research into practice.
The City of Hope has a long and impressive history of groundbreaking discoveries in the field of diabetes. It spans more than four decades of intense investigation since Rachmiel Levine, M.D., who discovered the role of insulin in glucose transport, launched diabetes research at City of Hope.
Arthur D. Riggs, Ph.D., chairs
the Department of Diabetes
and Metabolic Diseases Research.
The Department of Diabetes and Metabolic Diseases Research is now chaired by
Arthur D. Riggs
, Ph.D., another renowned researcher and pioneer in the field.
Riggs is recognized for his work on the synthesis of the first man-made gene and the use of synthetic genes for the production of human insulin. This first practical source of human insulin has largely replaced porcine- or bovine-derived insulin and has become the standard of care for diabetes worldwide.
Riggs continues to break ground in the battle against cancer, particularly in the area of epigenetics.
The department headed by Riggs encompasses two divisions, which interface between diabetes research and translational medicine:
The Division of Developmental & Translational Diabetes and Endocrine Research is acclaimed for its islet cell transplantation program, which offers an increasingly viable treatment option for Type 1 diabetes.
The Division of Molecular Diabetes Research is at the forefront of research on the complications of diabetes, and its researchers were among the first to study epigenetic changes in diabetes.
The Department of Diabetes and Metabolic Diseases Research includes as its primary goals:
Understanding the genetic and molecular signaling mechanisms that lead to diabetes and its complications
Advancing islet cell transplantation and related treatments for type 1 diabetes by developing better methods to prevent rejection and cure autoimmunity and by developing improved sources of islets or insulin-producing beta cells
Developing drugs that precisely target the receptor molecules responsible for diabetes
Studying the relationship between diabetes and cancer in order to better understand cancer etiology (and interplay at the metabolic level between these complex diseases). Specifically, developing systems biology data analysis framework to quantify and model diabetes and cancer molecular pathways
Designing interventions that address molecular targets common to both diabetes and cancer, through targeted, personalized pharmacotherapy.
The Division of Developmental and Translational Diabetes and Endocrine Research, directed by Fouad Kandeel, M.D., Ph.D., has translated landmark scientific discoveries into treatments that have improved the lives of diabetic patients around the world. The expansion of the Leslie & Susan Gonda (Goldschmied) Diabetes & Genetic Research Center has enabled us to bolster our efforts in the fight against diabetes simultaneously on multiple fronts: from developmental research starting in our state-of-the-art laboratories to clinical investigations leading to innovative patient care.
Fouad Kandeel, M.D., Ph.D., directs
the Division of Developmental and
Translational Diabetes and
Our goal is to bring the latest scientific findings into medical practice as quickly as possible. Researchers in our division conduct laboratory, translational and clinical research with the goal of improving our understanding of the disease process and guiding the development of new diagnostic, prognostic, and therapeutic interventions.
Here, we focus on stem cell biology and development, translational immunology, islet isolation and distribution, islet quality assessment, islet imaging, islet encapsulation and isolation, and new drug discoveries.
We are also developing a mobile device that combines a live glucose monitor with an automatic insulin delivery pump system. This “artificial pancreas” will free patients from periodic self-monitoring, as well as allow more accurate control of blood glucose levels. City of Hope researchers are working with the device manufacturer to optimize performance, and preparations are being made to test the device in newly transplanted islet recipients in order to provide maximum protection of islets from the harmful effects of high blood sugar.
Imaging islet cells within the body is greatly needed to elucidate the mechanisms underlying type 1 diabetes development and monitor islet cells following transplant. New cell-imaging approaches developed at City of Hope have been used to track islet cell survival and function in animal models and have been successfully applied in a human case of pancreatic tumor.
City of Hope Islet Cell Transplant Program
City of Hope is studying the
safety and effectiveness of
transplanting islet cells
as a treatment for
type 1 diabetes.
City of Hope is conducting clinical trials to study the safety and effectiveness of islet transplantation as a treatment for type 1 diabetes. City of Hope performed its first islet transplantation in 2004 and performed dozens more in the Islet Transplantation Alone and Islet After Kidney Transplantation trials. The current T cell-depleting trial will help answer the question of whether temporarily reducing or eliminating the recipient’s T cells at the time of islet transplantation will improve short- and long-term transplant results in patients with type 1 diabetes. The study also includes an assessment for changes in the quality of life after islet transplantation.
To qualify for the study, candidates must have type 1 diabetes, be between the ages of 18 and 68, and have the ability and willingness to comply with a post-transplant regimen that includes taking immunosuppression medications, frequent clinic visits and laboratory testing, using reliable contraception, maintaining detailed records of blood glucose levels, insulin doses, medications and completing detailed follow-up studies for up to five years.
Candidates who have received a prior kidney transplant for diabetic kidney failure may also participate in the study, if they have a stable kidney transplant for at least three months on specific commonly used anti-rejection medications.
For clinical transplant matters you may contact us by calling (866) 44 ISLET (47538) or e-mail us at email@example.com.
Global diabetes health initiative
There is a global need for a cost-effective solution to simplify diabetes management and minimize time spent on expensive and unstructured treatment plans. This solution must simultaneously improve patient participation in behavior modification and medication regimes.
The center's physicians and scientists, led by Fouad Kandeel, M.D., are collaborating with diabetes scientists and clinicians in Europe to develop a fully automated patient-management system that can be utilized on a global scale.
The ADAMS (Adaptive Diabetes Algorithm Managements System) platform is software that is designed to generate an automated, interventional treatment plan tailored to each patient. It takes into account culturally relevant dietary and behavioral issues and has the potential to streamline the efficiency of diabetes care around the world.
Each year, City of Hope hosts an annual diabetes and obesity symposium in memory of the late Dr. Rachmiel Levine, the scientist responsible for clarifying the nature of insulin action.
The 14th Annual Rachmiel Levine Symposium, entitled "Advances in Diabetes Research," will cover recent scientific advances in type 1 and type 2 diabetes and will highlight results of recent diabetes clinical trials.
It will also include poster sessions where promising young investigators can present their work, and debate sessions with world leaders in areas of controversy in diabetes research and clinical care.
City of Hope researchers including Rama Natarajan, Ph.D., director of the Division of Molecular Diabetes Research, have been selected to speak at the symposium.
The event is scheduled for March 12 – 15, 2014, in Pasadena.
Researchers and clinicians at City of Hope are engaged in ongoing communication and interaction to bring work from the lab to the bedside. Meet the researchers in the Division of Developmental & Translational Diabetes and Endocrine Research:
, M.D., Ph.D. - division director and professor
Islet cell transplantation
, Ph.D. - associate research professor
Islet cell transplantation, epigenetics, and diabetic biomarkers
H. Teresa Ku
, Ph.D. - associate professor
Stem cell therapy for type 1 diabetes; in vitro differentiation of human and mouse embryonic stem cells towards pancreatic lineage cells; identification, purification and characterization of embryonic and adult pancreatic stem/progenitor cells
, M.D., Ph.D. - research professor
Extrahepatic islet transplantation; prevention of islet loss for transplantation
, Ph.D. - associate research professor
Islet cell proliferation, differentiation and cryopreservation; aging in the human pancreas
The Division of Molecular Diabetes Research, directed by Rama Natarajan, Ph.D., is at the forefront of research on the complications of diabetes and was the first to study epigenetic changes in diabetic complications.
Rama Natarajan, Ph.D., directs the Division
of Molecular Diabetes Research.
Research leading to new therapies
Basic science research in molecular biology, biochemistry and immunology provides the foundation that drives the development of new therapies for diabetes and related complications. City of Hope scientists in this division are performing cutting-edge research in these areas.
Battling the complications of diabetes
Diabetes is the leading cause of kidney failure and a significant risk factor for the development of vascular complications like atherosclerosis. Our researchers are working to determine molecular mechanisms and factors mediating these complications and to develop strategies to prevent and reverse these complications. The researchers' study of atherosclerosis and kidney disease includes both diabetic animal models and humans.
Scientists in this division are examining the molecular links between diabetes, obesity, metabolism, cancer and aging, including the role of various nuclear receptors.
Gene and cell-based therapies
Translational approaches using small molecules are also being investigated. Researchers are using potential gene therapy and RNA interference translational approaches to inhibit key genes associated with diabetic complications. They are also developing synthetic small molecules to target genes that promote obesity and related metabolic changes.
Our researchers have identified a molecular link between physical activity and insulin sensitivity. They are using animal models to characterize key mechanisms in exercise's effects on skeletal muscle's energy metabolism and growth.
In addition, our researchers are performing important studies to develop novel methods to induce immune tolerance for the treatment of type 1 diabetes and also identify new cellular targets that can lead to cell-based therapies for diabetes. The results of these studies with immune cells can lead to more effective approaches in the treatment diabetes and to improved success of islet-cell transplantation.
Overall, this division within the Department of Diabetes and Metabolic Research uses several state-of-the-art computational and systems biology data-analysis methods; genomic and epigenomic profiling approaches; novel transgenic mouse models; and translational approaches with small molecules, antibody and cell-based therapies in animal models and humans in its quest to advance the field of diabetes research.
, Ph.D., F.A.H.A., F.A.S.N. - division director and professor
Identification of the molecular mechanisms underlying the accelerated cardiovascular and renal disease observed in diabetic patients and in obese subjects; role of epigenetics, microRNAs and other non-coding RNAs; and inflammatory responses in islet destruction
, Ph.D. - associate professor
Genetic and epigenetic regulation of diabetes; stem cell and drug development for diabetes
, Ph.D. – associate professor
Characterization of transcriptional mechanisms regulating skeletal muscle metabolic adaptations during growth and differentiation and in response to physiologic stress; the etiologic role of orphan nuclear receptors in obesity and type 2 diabetes
, Ph.D. – professor
Development of methods to induce immune tolerance; identification of novel cellular and molecular targets to improve cell-based therapy for diabetes
, M.D. - professor
Induction of mixed chimerism for reversal of autoimmunity, beta cell regeneration, and transplantation immune tolerance
City of Hope researchers have built the foundation of scientific knowledge upon which the understanding and treatment of diabetes are based.
Engineering synthetic insulin
In the late 1970s,
, Ph.D., and Keiichi Itakura, Ph.D., produced synthetic human insulin using bacteria. It became the first genetically engineered product approved by the Food and Drug Administration and today is used worldwide by millions of people with diabetes. The breakthrough made insulin more available and affordable and helped launch the biotechnology industry.
City of Hope researchers have made numerous breakthoughs, including in islet-cell transplantation and in the understanding of islet dysfunction.
Perfecting islet transplantation protocols
, M.D., Ph.D., perfected clinical islet-cell transplantation protocols and has developed imaging methods that enable physicians to more monitor in real time the health of islets after transplantation.
Targeting diabetic complications
, Ph.D., and Jerry Nadler, M.D., conducted research dealing with diabetic complications and islet dysfunction. Their work has led to the identification of novel therapeutic targets and agents for the treatment of diabetic complications. Natarajan was also the first to demonstrate the role of epigenetics in diabetic vascular inflammation and in the metabolic memory phenomenon.
Her laboratory was also the first to demonstrate how microRNAs (small, non-coding RNAs) can cause the overproduction of collagen, which creates damage that can lead to kidney abnormalities and renal dysfunction. She used therapeutic interventions to block these microRNAs, slowing the cells’ harmful overproduction of collagen and other proteins and kidney damage.
Diagnosing type 1 diabetes sooner
, Ph.D., has developed a new method of diagnosing type 1 diabetes. His research team detected unique markings on the DNA of insulin-producing cells. When these cells die during the progression of type 1 diabetes, the markings can be detected on DNA that circulates in the blood. This method can be used to diagnose type 1 diabetes before complications and can be used to test the effectiveness of new treatments.
To read about more of City of Hope researchers’ accomplishments, including the 1940s discovery by Rachmiel Levine, M.D., of insulin’s role in processing sugars, read our Diabetes Program History page.
Using computer science-based approaches to create individualized treatment plans
City of Hope researchers are developing a high-tech analytic tool that promises to revolutionize the way diabetes is treated. The treatment platform uses the combination of both data-driven and expert-based algorithms to generate validated individualized treatment plans. Advanced Diabetes Algorithm Management System, or ADAMS, starts by gathering information on the patient’s health, treatment preferences and other epidemiological and cultural factors. The data is processed using the model-fitting software that gives the physicians not only a basic “overview” of how a patient’s body is metabolizing glucose, but also the results of in silico simulations showing a specific intervention’s likely impact on a patient’s metabolic footprint. Thus, the patient is armed with a comprehensive treatment plan and continued feedback on diet, exercise and medication.
Fouad R. Kandeel
, M.D., Ph.D., director of the Division of Developmental & Translational Diabetes and Endocrine Research, who is leading this project, believes the program can vastly improve long-time clinical outcomes for large populations of diabetic patients across the globe. Kandeel is directly collaborating with
, Ph.D., a leader in the field of developing systems biology data analysis methodology, who is working on adapting his secondary data analysis tools to clinical data.
Identifying mechanisms and drug targets for diabetic complications
Diabetes is the leading cause of kidney failure and a significant risk factor for the development of vascular complications like atherosclerosis.
, Ph.D., director of the Division of Molecular Diabetes Research, is studying mechanisms of atherosclerosis and kidney disease in diabetes. She is using cell, animal and human models to demonstrate how diabetes leads to increased inflammation in blood and kidney cells and is devising approaches to interfere with the production of these inflammatory molecules to slow down diabetic vascular complications
Her team has also studied a gene-control mechanism called RNA silencing, which may play a key role in diabetic kidney disease. In it, cells employ pieces of genetic material called microRNA, or miRNA, to turn genes off. The researchers have identified a key miRNA that creates an overproduction of collagen, which causes damage that can lead to kidney disease and renal dysfunction. By controlling key miRNAs in the kidney, the researchers seek to slow down the cells’ overproduction of collagen and similar proteins and potentially control diabetic kidney disease. They are also similarly examining miRNAs and related molecules that promote inflammation in blood cells and blood vessels under diabetic conditions and approaches to interfere with their actions to control cardiovascular complications of diabetes.
City of Hope researchers are investigating
new ways to generate insulin-producing
cells from stem cells.
Generating insulin-producing cells from stem cells
One of the major roadblocks to translating stem cell research from the lab to the clinic is the low yield of insulin-producing cells from stem cells.
, Ph.D., the department chair, is collaborating with
Hsun Teresa Ku
, Ph.D., on ways to generate insulin-producing cells from stem cells.
The team is creating new technologies to accomplish this, including synthetic extracellular matrices, structures found in the connective tissues of animals, and genetically reprogram them to adopt a new identity and function.
Targeting a key to metabolic syndrome
, M.D., is studying the role of glutathione metabolism in the development of cancer and type 2 diabetes. He silenced the gene that expresses the protein RLIP76, increasing resistance to the development of chemically induced cancers in animal models. Furthermore, the models showed reduced blood sugar, cholesterol and triglycerides despite a high-fat diet. These findings are expected to lead to the development of novel drugs that targets RLIP76 in order to treat obesity, metabolic syndrome and cancer.
Creating a drug to mimic the benefits of exercise
In order to develop treatments that slow or prevent the development of type 2 diabetes, researchers must understand the ways in which various insulin responsive tissues respond to fluctuations in diet and energy demand. The laboratory of
, Ph.D., investigates mechanisms governing mitochondrial energy metabolism and growth of skeletal muscle in healthy and diseased states. The capacity of skeletal muscle to regulate whole body energy balance, glucose and lipid utilization and to prevent the development of obesity and insulin resistance is determined by its oxidative capacity and it overall mass. Her group has discovered that the Estrogen-related Receptors (ERRs) control interrelated programs of muscle energy metabolism and growth. ERRs control levels of proteins needed for energy metabolism and muscle contraction. These factors are essential for directing metabolic enhancements caused by endurance exercise. Her laboratory is investigating whether targeting ERR genetically and novel drugs could prevent diet-induced obesity or mimic the beneficial effects of exercise on whole body glucose control.
T cells are the focus of
Chih-Pin Liu, Ph.D.
Suppressing a patient’s immune imbalance
, Ph.D., is developing a new method to correct immune imbalance that may cause diabetes by taking a patient’s own regulatory T cells, which help to maintain balance in the immune system, and expanding them in the laboratory, then re-administering the cells to the diabetic patient. Liu’s promising research has already shown that Treg cells fortified in this way are as potent as normal Treg cells in suppressing the pathogenic immune imbalance that leads to a patient’s inability to produce insulin.
From nature, a potential treatment for diabetes
The lab of
, Ph.D., recently discovered that a chemical derivative of the barbary plant, berberine, may block diabetes by activating a receptor that increases the body’s sensitivity to insulin and helps maintain glucose balance. Berberine, which is approved by the Food and Drug Administration to treat other conditions, could be tested in humans for its potential effect on diabetes. Huang is also interested in small RNAs known as microRNAs (miRNAs), which have emerged as key regulators of genes related to metabolism and diabetes. He discovered a specific miRNA that, when overproduced in animal models, improves insulin sensitivity and prevents obesity-related metabolic complications. That miRNA is now a potential target for type 2 diabetes therapies.
Real-time imaging of islet cells after transplant
, M.D., Ph.D., is also developing methods to directly monitor islet survival and function after transplantation into the liver using a radio-labeled protein developed at City of Hope that binds to human islet cells, an approach that has been successful in mouse models. Real-time imaging of the transplanted islet graft will provide critical information about cell health and dysfunction and help to ensure graft survival. It could also be used to monitor native islet cells in patients newly diagnosed with type 1 diabetes. This leading-edge technology will allow physicians to assess the success of islet cell translation with more accuracy and timeliness than traditional assessment methods.
Defu Zeng, M.D., front, pictured with former post-doctoral student Dong-Chang Zhao, is investigating a non-toxic method of inducing mixed chimerism as part of a cure for type 1 diabetes.
Developing a curative therapy for overt type 1 diabetes
Autoimmune type 1 diabetes is caused by autoimmune destruction of insulin-producing cells. Cure of overt type 1 diabetes requires the simultaneous stoppage of autoimmunity and regeneration of insulin-producing cells. At this time, the only therapy with the potential to do this is the combination of induction of mixed chimerism and administration of growth factors that has been recently developed by the laboratory of
, M.D. Mixed chimerism is the co-existence of donor and recipient hematopoiesis and immune system that can cure autoimmunity. Once autoimmunity is stopped, injection of growth factors can augment the regeneration of insulin-producing cells and subsequently cure the disease.
Mixed chimerism can be established by hematopoietic cell transplantation (HCT), but the classical HCT procedure requiring total body irradiation or high-dose chemotherapy has strong toxicity and the potential to cause graft versus host disease (GvHD). Zeng’s lab has found that anti-CD3 monoclonal antibodies can replace total body irradiation or high dose chemotherapy for induction of mixed chimerism. This new procedure is non-toxic and avoids the side effect of GvHD. Now, in collaboration with
, Ph.D., the department chairman, Zeng’s lab is working on translating this novel therapy into clinical application by making antibodies that can be used in patients and by conducting experiments with large animal models.
Exploring the epigenetic and genetic underpinnings of obesity and diabetic complications
, Ph.D., is leading examinations into the role of epigenetics in diabetes and its complications, as well as genetic variations that make some people more susceptible to obesity and metabolic disease. Susceptibility to both obesity and diabetes depends on genetics and environmental factors (like high calorie and high fat diets) that affect our epigenes or epigenetics. Epigenetics refers to changes that are made to our genes and can be passed on to future generations — but are not written into our DNA. Dr. Natarajan’s laboratory is using state-of-the-art epigenome profiling to decipher epigenetic changes that promote inflammation and metabolic memory in diabetes, and also predispose to diabetic vascular and kidney disease in animal and human subjects. Because epigenetic changes are reversible, this research could lead to the development of epigenetic drugs to treat diabetes and its debilitating complications.
Furthermore, in collaboration with other researchers, Natarajan is using novel animal models to map specific genome regions that become active when the subjects consume a diet high in fat and sugar. The goal is to discover unique genes and develop therapies to turn them on or off to give a patient the same genetic protection that some members of the general population have against obesity, regardless of diet.
Read more about City of Hope projects on each researcher’s individual page.
Hematopoietic cell transplant patients who undergo what’s known as myeloablative conditioning (that is, high-intensity chemotherapy and radiation) – and who have shorter telomeres (chromosome “end caps”) – may be at greater risk for cognitive impairment after transplant, City of Hope researchers have foun...
The fourth in a series about how to give, and give back, during the holiday season ... Giving back during the holidays (or year-round) doesn’t have to come in the form of cash, toys or tangible gifts. In fact, it can be done at no cost: One way is by volunteering. Local hospitals, animal shelters and
Bishop J. Jon Bruno will be one of 11 former City of Hope patients riding atop our float on New Year’s Day. Read other riders’ stories and learn more about the float, “Turning Hope and Dreams into Reality.” ** After returning home from cancer treatment at City of Hope in May 2012, J. Jon...
In addition to toasting, feting and feasting, another tradition of the holiday season is taking stock of the year about to end, and making plans for the one about to begin. Often, these happen in the form of the New Year’s resolution, which often begins as a lofty good intention and becomes an afterthought befo...
For many people, the holiday calendar is packed with parties, and superfoods – found by City of Hope scientists to have the potential to fight cancer – are an easy and good-for-you addition to a holiday menu. Take mushrooms, for example. Researcher Shiuan Chen, Ph.D., has found that white button mushrooms can h...
As treatment options expand, and researchers learn more about individual tumors, a critical component of cancer treatment becomes determining the most effective tool to treat an individual patient. Equally important to knowing when to perform a surgery is knowing when not to. Breast cancer experts debate the be...
Many people have heard of the vaccine against human papillomavirus (HPV), but they often don’t know how well it works to lower the risk of cervical cancer, a new study has found. In fact, few people actually talk to their doctors about the vaccine. The study, which was funded by the American Cancer Societ...
Myelodysplastic syndrome, once known as “preleukemia,” is a disease of the blood and bone marrow that often attacks people who have survived initial cancer treatment. “Good Morning America” co-host Robin Roberts, for example, was diagnosed with the syndrome, known as MDS, in June 2012, five years after successf...
Five years ago this month, Jaylon Fong was diagnosed with leukemia. He underwent chemotherapy and a rigorous treatment plan before going into remission. But that proved to be only his first battle with the disease. He was rediagnosed in 2012 and suffered a central nervous system relapse. Today, he is a two-time...
The third in a series about how to give, and give back, during the holiday season … Giving back this holiday season is easier than ever. Retailers are increasingly embracing the spirit of the holiday season by partnering with charities and nonprofit organizations to benefit the greater good. These relatio...
Cancer screening always carries risks and benefits – usually trading a degree of “overdiagnoses” for finding cancers at early stages, when they are least lethal and most treatable. From mammography to PSA testing, what to screen, how to screen and when to screen remains a source of debate and discussion among t...
For many people, the holidays are a time of joy and celebration. However, for patients with cancer and other serious illnesses — and for survivors — the season can be a time of overwhelming stress. “For a number of different reasons, [the holiday season] is stressful for a lot of people, and adding an ill...
In April of 2012, Debbie Brooks received her regular mammogram – and it turned up no signs of cancer. As all women are recommended to do, Brooks remained vigilant, performing regular self-exams. That’s when she found a lump – sometimes she could detect it, sometimes not. She followed up with her doctor to have ...
For those who have battled cancer, each tomorrow is, in reality, a dream come true. On Jan. 1, former City of Hope patients will see another dream come true: They’ll be riding atop City of Hope’s float in the 2014 Tournament of Roses Parade. The theme of this year’s float is “Turning Ho...
Prostate cancer is one of the most common types of cancer affecting men, with one in six American men receiving the diagnosis in their lifetime. In most cases, the disease grows slowly and causes no problems. But some prostate cancers are fast-moving and lethal, causing more than 29,000 deaths annually because ...